Sofpironium bromide is a structural analogue of glycopyrrolate, an anticholinergic agent. Positive topline results were announced from 2 identical phase 3 studies evaluating sofpironium bromide in ...

The FDA approved sofpironium topical gel 12.45% (Sofdra) for primary axillary hyperhidrosis, according to a statement from Botanix Pharmaceuticals. The approval stipulates use in adults and children 9 ...

Please provide your email address to receive an email when new articles are posted on . Candesant Biomedical announced positive results from its pilot study on the targeted alkali thermolysis patch, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has cleared Brella, a noninvasive, targeted alkali thermolysis product that treats primary axillary ...

Excessive sweating, or hyperhidrosis, is a quite unpleasant disease that brings both physical and psychological discomfort.

The Food and Drug Administration has approved a topical anticholinergic, sofpironium topical gel, 12.45%, for the treatment of primary axillary hyperhidrosis in adults and children aged ≥ 9 years.

Hyperhidrosis most commonly affects the armpits, followed by the palms of the hands and the soles of the feet. Impairment of quality of life differs based on where primary hyperhidrosis manifests on ...

Sofpironium bromide indirectly reduces the rate of sweating by preventing the stimulation of acetylcholine receptors that are located on sweat glands. The Food and Drug Administration (FDA) has ...

NASHVILLE, Tenn., March 18, 2023 /PRNewswire/ -- Candesant Biomedical ("Candesant"), a private medical device company focused on the development and commercialization of non-invasive treatments for ...

The US Food and Drug Administration (FDA) today cleared the first patch to reduce excessive underarm sweating for adults with primary axillary hyperhidrosis. The single-use, disposable, ...

NASHVILLE, Tenn., March 9, 2023 /PRNewswire/ -- Candesant Biomedical ("Candesant"), a private medical device company focused on the development of non-invasive treatments for hyperhidrosis or ...

MENLO PARK, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering ...